First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

August 3, 2021 updated by: Rockefeller University

A Phase 1, Dose Escalation, First-in-human Study of the Safety and Pharmacokinetics of the Subcutaneous and Intravenous Administration of 10-1074-LS Alone and in Combination With 3BNC117-LS in HIV-infected and HIV-uninfected Individuals

This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and HIV-uninfected individuals.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The proposed study is a Phase 1, dose escalation cohort study of 10-1074-LS alone or in combination with 3BNC117-LS, administered intravenously and subcutaneously in HIV uninfected and HIV-1 infected individuals.

Study participants will be administered a single intravenous infusion of 10-1074-LS at 3, 10 or 30 mg/kg, single infusions of the combination of 10-1074-LS and 3BNC117-LS, each dosed at 30 mg/kg, or subcutaneous injections of 10-1074-LS alone or in combination with 3BNC117-LS, and three subcutaneous injections of 10-1074-LS in combination with 3BNC117-LS at three dose ratios. The first four groups administered subcutaneous injections of the product(s) will be randomized, double-blinded, and placebo-controlled to assess potential differences in safety and tolerability of the antibody formulation versus the formulation buffer alone. In the dose ratio portion of the study, participants will be randomized into one of three groups, but the products will be administered in an open-label manner. Groups administered intravenous infusions will be enrolled in an open-label manner.

PART A

Group 1A (n=8) - HIV-uninfected individuals will be administered one 1 mL (approximately 150 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.

Group 1B (n=8) - HIV-uninfected individuals will be administered one 2 mL (approximately 300 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.

Group 2A (n=3) - HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 3 mg/kg.

Group 2B (n=3) - HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg.

Group 2C (n=3) - HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.

Group 3B (n=3) - HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg.

Group 3C (n=3) - HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.

PART B

Part B will begin after the Safety Monitoring Committee (SMC) evaluates available safety data from Part A, as detailed below. The SMC will also review available safety data with 3BNC117-LS administered intravenously collected under protocol YCO-0946 prior to enrollment in Part B of this study. The SMC will also review subcutaneous dosing at approximately 150 mg (1 mL) and 300 mg (2 mL), collected under IND 131873 when available and prior to enrollment in Part B of this study.

Group 4A (n=8) - HIV-uninfected individuals will be administered one 2 mL (approximately 150 mg of each mAb) subcutaneous injection of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.

Group 4B (n=8) - HIV-uninfected individuals will be administered two 2 mL (approximately 300 mg of each mAb) subcutaneous injections of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.

Group 5 (n=5) - HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.

Group 6 (n=5) - HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.

Group 7 (n=6) HIV-uninfected individuals will be administered three subcutaneous injections of 10-1074-LS (100 mg) admixed with 3BNC117-LS (200 mg) (2 mL).

Group 8 (n=6) HIV-uninfected individuals will be administered three subcutaneous injections of 10-1074-LS (75 mg) admixed with 3BNC117-LS (225 mg) (2 mL).

Group 9 (n=6) HIV-uninfected individuals will be administered three subcutaneous injections of 10-1074-LS (60 mg) admixed with 3BNC117-LS (240 mg) (2 mL).

Following mAb or placebo administration, study participants will return for safety assessments on days 1 and 3, and weeks 1, 2 and 4 following each dose, then bi-monthly or monthly until the end of study follow up.

All participants will be followed for 48 weeks after last mAb or placebo administration. Serum samples for PK measurements will be collected before and at the end each mAb or placebo administration and at multiple subsequent time points during study follow up.

Samples will also be collected for measurement of HIV-1 plasma RNA levels before 10-1074-LS and 3BNC117-LS infusions and at follow up visits according to protocol.

Study Type

Interventional

Enrollment (Actual)

77

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • New York, New York, United States, 10065
        • The Rockefeller University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Groups 1A-1B, 2A-2C, 4A-4B, 5, 7, 8, 9 (HIV-uninfected):

  • Males and females, age 18 to 65
  • Amenable to HIV risk reduction counseling and agrees to maintain behavior consistent with low risk of HIV exposure.
  • If sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use two effective methods of contraception (i.e.

condom with spermicide, diaphragm with spermicide, hormone-eluting IUD, hormone-based contraceptive with condom) from 10 days prior to and nine months after 10-1074-LS and/or 3BNC117-LS administration.

- Female study participants of reproductive potential are defined as pre-menopausal women who have not had a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, tubal ligation or salpingectomy). Women are considered menopausal if they have not had a menses for at least 12 months and have a FSH of greater than 40 IU/L or if FSH testing is not available, they have had amenorrhea for 24 consecutive months.

Groups 3B-3C, 6 (HIV-infected):

  • Males and females, age 18 to 65.
  • Confirmed HIV-1 infection.
  • HIV-infected individuals on ART with HIV-1 plasma RNA levels < 50 copies/mL.
  • Current CD4+ T cell count > 300 cells/μl.
  • If sexually active male or female, and participating in sexual activity that could lead to pregnancy or transmission of HIV, agrees to use two effective methods of contraception (i.e. condom with spermicide, diaphragm with spermicide, hormone-eluting IUD, hormone-based contraceptive with condom) from 10 days prior to and nine months after 10-1074-LS and/or 3BNC117-LS administration.

Exclusion Criteria:

Groups 1A-1B, 2A-2C, 4A-4B, 5, 7, 8, 9 (HIV-uninfected):

  • Confirmed HIV-1 or HIV-2 infection.
  • Weight > 110 kg (subcutaneous groups only: 1A-1B, 4A-4B).
  • History of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant
  • Any clinically significant acute or chronic medical condition (such as autoimmune diseases) that in the opinion of the investigator would preclude participation.
  • Within the 12 months prior to enrollment, the participant has a history of sexually transmitted infection.
  • Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood.
  • Laboratory abnormalities in the parameters listed:
  • Absolute neutrophil count ≤ 1,500 cells/μL;
  • Hemoglobin ≤ 11 gm/dL if female; ≤ 12.5 gm/dL if male;
  • Platelet count ≤ 125,000 cells/μL;
  • ALT ≥ 1.25 x ULN;
  • AST ≥ 1.25 x ULN;
  • Alkaline phosphatase ≥ 1.5 x ULN;by the trial physician within the last 6 months.
  • Pregnancy or lactation.
  • Any vaccination within 14 days prior to mAb infusions.
  • Receipt of any experimental HIV vaccine or monoclonal antibody therapy of any kind in the past.
  • History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions.
  • Individuals with known hypersensitivity to any constituent of the investigational products.
  • Receipt of another investigational product currently or within the past 12 weeks, or expected concurrent participation in another study in which investigational products will be administered.

Groups 3B-3C, 6 (HIV-infected):

  • Have a history of AIDS-defining illness within 3 years prior to enrollment.
  • History of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months.
  • Any clinically significant acute or chronic medical condition (such as autoimmune diseases), other than HIV infection, that in the opinion of the investigator would preclude participation.
  • Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood.
  • Laboratory abnormalities in the parameters listed below:
  • Absolute neutrophil count ≤ 1,000 cells/μl;
  • Hemoglobin ≤ 10 gm/dL;
  • Platelet count ≤ 100,000 cells/μl;
  • ALT ≥ 1.5 x ULN;
  • AST ≥ 1.5 x ULN;
  • Alkaline phosphatase ≥ 1.5 x ULN;
  • Total bilirubin > 1 x ULN;
  • eGFR < 60 mL/min/1.73m2.
  • Pregnancy or lactation.
  • Any vaccination within 14 days prior to MAb infusions.
  • Receipt of any experimental HIV vaccine or monoclonal antibody therapy of any kind in the past.
  • History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions.
  • Individuals with known hypersensitivity to any constituent of the investigational products.
  • Receipt of another investigational product currently or within the past 12 weeks, or expected concurrent participation in another study in which investigational products will be administered.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group 1A
HIV-uninfected individuals will be administered one 1 mL (approximately 150 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 1B
HIV-uninfected individuals will be administered one 2 mL (approximately 300 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 2A
HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 3 mg/kg.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 2B
HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 2C
HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 3B
HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 3C
HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 4A
HIV-uninfected individuals will be administered one 2 mL (approximately 150 mg of each mAb) subcutaneous injection of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Subcutaneous injection of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Intravenous infusion of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 4B
HIV-uninfected individuals will be administered two 2 mL (approximately 300 mg of each mAb) subcutaneous injections of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Subcutaneous injection of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Intravenous infusion of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 5
HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Subcutaneous injection of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Intravenous infusion of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 6
HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Subcutaneous injection of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Intravenous infusion of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 7
HIV-uninfected individuals will be administered three subcutaneous injections of 10-1074-LS (100 mg) admixed with 3BNC117-LS (200 mg) (2 mL) at weeks 0, 12, and 24.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Subcutaneous injection of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Intravenous infusion of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 8
HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (75 mg) admixed with 3BNC117-LS (225 mg) (2 mL) at weeks 0, 12, and 24.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Subcutaneous injection of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Intravenous infusion of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Experimental: Group 9
HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (60 mg) admixed with 3BNC117-LS (250 mg) (2 mL) at weeks 0, 12, and 24.
Drug: 10-1074-LS
Subcutaneous injection of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 10-1074-LS
Intravenous infusion of 10-1074-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Subcutaneous injection of 3BNC117-LS
Other Names:
  • Monoclonal antibody
Drug: 3BNC117-LS
Intravenous infusion of 3BNC117-LS
Other Names:
  • Monoclonal antibody

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The number of participants who experience adverse events within 2 weeks after 10-1074-LS intravenous infusions and subcutaneous injections.
Time Frame: 2 weeks
Adverse events include signs, symptoms and laboratory abnormalities, in addition to local and systemic reactogenicity adverse events.
2 weeks
The number of participants who experience adverse events within 2 weeks after 10-1074-LS and 3BNC117-LS intravenous infusions and subcutaneous injections.
Time Frame: 2 weeks
Adverse events include signs, symptoms and laboratory abnormalities, in addition to local and systemic reactogenicity adverse events.
2 weeks
Elimination half-life (t1/2) of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups.
Time Frame: 48-72 weeks
Elimination half-life (t1/2) of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups.
48-72 weeks
The clearance (CL) of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups.
Time Frame: 48-72 weeks
The clearance (CL) of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups.
48-72 weeks
The volume of distribution (Vz) of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups
Time Frame: 48-72 weeks
The volume of distribution (Vz) of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups
48-72 weeks
Area under the curve of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups.
Time Frame: 48-72 weeks
Area under the curve of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups.
48-72 weeks
Decay curve of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups.
Time Frame: 48-72 weeks
Decay curve of 10-1074-LS, when administered alone and in combination with 3BNC117-LS in all study groups.
48-72 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of induced anti-10-1074-LS antibodies
Time Frame: 48-72 weeks
Frequency of induced anti-10-1074-LS antibodies
48-72 weeks
Level of induced anti-10-1074-LS antibodies
Time Frame: 48-72 weeks
Level of induced anti-10-1074-LS antibodies
48-72 weeks
Frequency of induced anti-3BNC117-LS antibodies
Time Frame: 48-72 weeks
Frequency of induced anti-3BNC117-LS antibodies
48-72 weeks
Level of induced anti-3BNC117-LS antibodies
Time Frame: 48-72 weeks
Level of induced anti-3BNC117-LS antibodies
48-72 weeks
The number of participants that experience who experience adverse events during the study follow up period after 10-1074-LS and/or 3BNC117-LS administration in all study groups.
Time Frame: 48-72 weeks
Adverse events include signs, symptoms and laboratory abnormalities
48-72 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Rockefeller University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 20, 2018

Primary Completion (Actual)

February 4, 2021

Study Completion (Actual)

February 4, 2021

Study Registration Dates

First Submitted

May 31, 2018

First Submitted That Met QC Criteria

May 31, 2018

First Posted (Actual)

June 13, 2018

Study Record Updates

Last Update Posted (Actual)

August 4, 2021

Last Update Submitted That Met QC Criteria

August 3, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • YCO-0971

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Human Immunodeficiency Virus

Clinical Trials on 10-1074-LS

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe